ConSynance is a clinical-stage virtual biopharmaceutical company focusing on rare diseases in the central nervous system. Our lead asset is CSTI-500, a small molecule first-in-class triple monoamine reuptake inhibitor (TRI) with the potential to benefit patients with Prader-Willi syndrome (PWS) and other related disorders. CSTI-500 was generally safe and well-tolerated in Phase I clinical trials in healthy humans and demonstrated CNS target engagement via PET that predicts efficacy in patients. ConSynance is currently recruiting for a Phase I study in PWS patients (clinicaltrials.gov: NCT05504395) to study the pharmacokinetics and safety in this patient population. We also have a preclinical candidate, CSTI-200, a small molecule, first-in-class GlyT-1 Inhibitor for the treatment of L-Dopa-induced dyskinesia (LID) in Parkinson’s disease (PD). Based on recent preclinical evidence, GlyT1 inhibition may have a niche in PD not only for the treatment of dyskinesia, but motor fluctuations and PD psychosis. CSTI-200 has a competitive mechanism of binding that provides a “self-regulating” property for potentially better tolerability compared with non-competitive GlyT-1 inhibitors. In 2021, we reached an asset purchase agreement with Harmony Biosciences for our second drug, (formerly CSTI-100, now renamed HBS-102.) This potential first-in-class MCHR1 antagonist has the potential to treat a variety of neurological disorders. ConSynance currently holds the license of this drug for the Greater China region and Harmony has global commercialization rights outside of Greater China.
